A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Pain Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00894699
• Other study ID #: ARX-C-007
• Status: Completed
• Phase: Phase 2
• First received: May 5, 2009
• Last updated: May 23, 2014
• Start date: June 2009
• Est. completion date: September 2009

Study information

• Verified date: May 2014
• Source: AcelRx Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patient must have provided written informed consent to participate in the study.

2. Male or female patient between 18 to 60 (inclusive) years of age.

3. Patient is planning to undergo an elective outpatient abdominal liposuction procedure.

4. Patient must be classified as American Society of Anesthesiologists (ASA) class I - III.

5. Patient must have Body Mass Index [BMI = weight (kg)/height (m2)] between 20 and 35, inclusively.

6. Female patients of childbearing potential must be using an effective method of birth control at the time of the screening visit and for 30 days following the dosing of study medication. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for =1 year, must be specified. Patients using hormonal forms of contraception must also be willing to use a barrier method of contraception from screening through 30 days following the dose of study medication.

7. Patient is willing to receive antibiotics as per the normal practice of the surgeon.

8. Patient understands that preoperative analgesics or anxiolytics are not permitted.

9. Patient is willing to avoid caffeine and alcohol use within 24 hours before the procedure.

10. The patient must be willing and able to understand the study procedures and the use of pain and anxiety scales, and to communicate meaningfully with the study personnel.

11. The patient must have a caregiver available to escort the patient home following the procedure.

Exclusion Criteria:

1. Patient who is expected to require less than 400 cc or more than 700 cc of abdominal fat removal during the procedure.

2. Patient has previously not responded to opioid analgesics for treatment of pain.

3. Patient has previously not responded to benzodiazepines for treatment of anxiety.

4. Patient is currently taking any opioid or has taken any opioid for more than 7 consecutive days of daily use within the past 3 months prior to the procedure.

5. Patient is currently taking any benzodiazepine or has taken any benzodiazepine for more than 7 consecutive days within the past 3 months prior to the procedure.

6. Patient is taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.

7. Patient has an allergy or hypersensitivity to opioids.

8. Patient who is currently taking anti-inflammatory drugs, including steroids.

9. Use of drugs which are P450 3A4 inducers or inhibitors within 30 days of dosing including alprazolam, chlorpheniramine, cimetidine, fluoxetine, haloperidol, ketoconazole, itraconazole, erythromycin, clarithromycin, sildenafil, simvastatin, St. John's Wort.

10. Patient who is taking calcium channel blockers or beta blockers.

11. Patient who will consume grapefruit, or products made with grapefruit, within 3 days of study medication dosing.

12. Patient with a history of chronic obstructive pulmonary disease (COPD) or any other respiratory condition or active pulmonary disease.

13. Patient currently has sleep apnea that has been documented by a sleep laboratory study.

14. Patient is a woman who is pregnant or lactating.

15. Patient has a history of an anxiety disorder.

16. Patients with oral mucositis or stomatitis.

17. Patient has a history of drug, prescription medicine, or alcohol abuse within the past 2 years.

18. Patient used an investigational drug or device within 30 days of screening visit.

19. Patient has undergone a liposuction procedure previously.

20. Patient has a history of migraine or chronic headache.

21. Patient who has a positive urine screen for drugs of abuse at screening or on the day of procedure.

22. Patient who has a positive alcohol screen on the day of the procedure.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety
• Pain
• Sedation

Intervention

Drug:
• Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
• Placebo NanoTab™
Single dose of sublingual placebo NanoTab™

Locations

Country	Name	City	State
United States	Lotus Clinical Research, Inc.	Pasadena	California

Sponsors (1)

Lead Sponsor	Collaborator
AcelRx Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)	The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period.	4 hour study period	Yes